case studies April 23

profileEmir7
Table-3-Asthma-and-COVID-19-2.docx

Table 3. Multivariable analyses of association between asthma and SAR-CoV-2 infection among children aged < 15 year

Variables

Model 1:

Unadjusted model

Model 2:

Adjusted for age and sex

Model 3:

Adjusted for nationality

Model 4:

Adjusted for cardiovascular disease and immunocompromised host

Model 5:

Adjusted for age and sex, cardiovascular disease, immunocompromised host

Model 6:

Adjusted for all covariates

RR (95% CI)

P-value

RR (95% CI)

P-value

RR (95% CI)

P-value

RR (95% CI)

P-value

RR (95% CI)

P-value

RR (95% CI)

P-value

Main exposure

Asthma

No

Reference

Reference

Reference

Reference

Reference

Reference

Yes

1.09 (0.86, 1.39)

0.460

1.04 (0.82, 1.32)

0.755

1.07 (0.85, 1.37)

0.556

1.09 (0.86, 1.38)

0.485

1.03 (0.81, 1.31)

0.783

1.03 (0.81, 1.31)

0.801

Covariates

Sex

Female

Reference

Reference

Reference

Male

0.98 (0.93, 1.04)

0.583

0.98 (0.93, 1.04)

0.581

0.98 (0.93, 1.04)

0.597

Age (years)

< 2

Reference

Reference

Reference

2 - < 6

1.35 (1.22, 1.51)

< 0.001

1.35 (1.22, 1.51)

< 0.001

1.31 (1.17, 1.47)

< 0.001

6 - < 12

1.47 (1.33, 1.62)

< 0.001

1.46 (1.33, 1.62)

< 0.001

1.41 (1.27, 1.56)

< 0.001

12 - < 15

1.47 (1.32, 1.63)

< 0.001

1.46 (1.31, 1.63)

< 0.001

1.40 (1.25, 1.57)

< 0.001

Nationality

Thai

Reference

Reference

Non-Thai

0.74 (0.65, 0.83)

< 0.001

0.86 (0.76, 0.98)

0.027

Cardiovascular diseases

No

Reference

Reference

Reference

Yes

0.68 (0.46, 1.02)

0.059

0.72 (0.48, 1.06)

0.097

0.72 (0.49, 1.07)

0.104

Immunocompromised host*

No

Reference

Reference

Reference

Yes

0.49 (0.18, 1.36)

0.171

0.47 (0.17, 1.31)

0.151

0.48 (0.18, 1.33)

0.157

RR, risk ratio; CI, confidence interval

Multivariable models were estimated by Poisson regression with robust standard error.

* Immunocompromised hosts include people who have at least one of the following malignancies (solid tumor or hematologic malignancy), diseases that are treated by corticosteroid immune suppressants and chemotherapy.